openPR Logo
Press release

Lawsuit filed for Investors who lost money with shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

05-05-2023 05:48 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares.

A lawsuit was filed on behalf of investors in Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares.

An investor, who purchased shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC), filed a lawsuit over alleged violations of Federal Securities Laws by Fulcrum Therapeutics, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) have certain options and for certain investors are short and strict deadlines running. Deadline: June 27, 2023. NASDAQ: FULC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Cambridge, MA based Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. One of the Company's lead product candidates is FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies. Over the course of 2022, Fulcrum submitted preclinical data to the U.S. Food and Drug Administration ("FDA") in connection with the Company's intention to file an Investigational New Drug application for FTX-6058 for the potential treatment of sickle-cell disease. On July 17, 2019, Fulcrum Therapeutics, Inc announced the pricing of its initial public offering ("IPO") of 4.5 million shares at $16.00 per share, for gross proceeds of $72.0 million.

On February 24, 2023, Fulcrum Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug application for its sickle-cell disease treatment, FTX-6058, due to previously reported preclinical data.

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) declined to as low as $5.17 per share on February 27, 2023.

Then, on March 9, 2023, before the market opened, Fulcrum Therapeutics, Inc announced business highlights and the Company's Q4 and full year 2022 financial results. The press release provided that in the clinical hold letter the Company received on February 24, 2023, the FDA referenced "preclinical data previously submitted in April, October and December 2022, and non-clinical and clinical evidence of hematological malignancies observed with other inhibitors of polycomb repressive complex 2 (PRC2)," and noted that "the profile of hematological malignancies observed in the non-clinical studies of FTX-6058 is similar to that observed with other inhibitors of PRC2, and that hematological malignancies have been reported clinically with other PRC2 inhibitors." Finally, the FDA requested that Fulcrum "further define the population where the potential benefit of continued treatment with FTX-6058 outweighs potential risk."

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) declined to as low as $2.25 per share on April 12, 2023.

The plaintiff claims that between March 3, 2022 and March 8, 2023, the Defendants made false and/or misleading statements and/or failed to disclose that the preclinical data submitted in support of FTX-6058 showed safety concerns regarding potential hematological malignancies, that the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058, that accordingly, the Company had overstated FTX-6058's clinical and/or commercial prospects, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) here

News-ID: 3041865 • Views:

More Releases from Shareholders Foundation

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly NASDAQ: SINA)
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made. If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: FLR) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp. (NYSE: SOC)
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp. Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Fulcrum

Facioscapulohumeral Muscular Dystrophy Market Anticipated to Expand Rapidly Duri …
DelveInsight's "Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Facioscapulohumeral Muscular Dystrophy, historical and forecasted epidemiology as well as the Facioscapulohumeral Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Facioscapulohumeral Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends f …
The Key Facioscapulohumeral Muscular Dystrophy Companies in the market include - Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche, Pfizer, Avidity Biosciences, Inc, and others. DelveInsight's "Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Facioscapulohumeral Muscular Dystrophy, historical and forecasted epidemiology as well as the Facioscapulohumeral Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and
Census Acquires Fulcrum to Enhance Data Collaboration and Modeling
The strategic acquisition will accelerate Census's roadmap for AI-led customer segmentation, personalization, and data modeling. San Francisco, CA, USA - July 17, 2024 - Census, the #1 data activation and reverse ETL platform [https://www.getcensus.com/blog/what-is-data-activation], has announced its acquisition of Fulcrum, a AI-led growth platform for business teams. Image: https://www.getnews.info/uploads/02a46bc0675193e89da14681ac87fa37.jpg AI-driven insights, operations, and agents are the future of how enterprises operate efficiently and impact business growth. Fulcrum and Census will create a foundation
Facioscapulohumeral Muscular Dystrophy (FSHD) Market Report 2032: Epidemiology D …
DelveInsight's "Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Facioscapulohumeral Muscular Dystrophy, historical and forecasted epidemiology as well as the Facioscapulohumeral Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Facioscapulohumeral Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Facioscapulohumeral Muscular Dystrophy
Biojet Fuels market: Players tapping Emerging Markets | Neste, Total, Fulcrum Bi …
The Biojet Fuels global market is thoroughly researched in this report, noting important aspects like market competition, global and regional growth, market segmentation and market structure. The report author analysts have estimated the size of the global market in terms of value and volume using the latest research tools and techniques. The report also includes estimates for market share, revenue, production, consumption, gross profit margin, CAGR, and other key factors.
Investigation announced for Investors in shares of Fulcrum Therapeutics, Inc. (N …
Fulcrum Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Fulcrum Therapeutics, Inc. regarding its business, its prospects and its operations were materially false